摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-AG ether;2-Arachidonylglyceryl ether;HU 310

中文名称
——
中文别名
——
英文名称
2-AG ether;2-Arachidonylglyceryl ether;HU 310
英文别名
2-icosa-5,8,11,14-tetraenoxypropane-1,3-diol
2-AG ether;2-Arachidonylglyceryl ether;HU 310化学式
CAS
——
化学式
C23H40O3
mdl
——
分子量
364.6
InChiKey
CUJUUWXZAQHCNC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.7
  • 重原子数:
    26
  • 可旋转键数:
    18
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.65
  • 拓扑面积:
    49.7
  • 氢给体数:
    2
  • 氢受体数:
    3

文献信息

  • [EN] IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS IMIDAZOLE UTILES COMME INHIBITEURS DE LA FAAH
    申请人:MERCK & CO INC
    公开号:WO2009152025A1
    公开(公告)日:2009-12-17
    The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.
    本发明涉及某些咪唑衍生物,其可用作脂肪酰胺水解酶(FAAH)的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方,以及这些化合物及其配方在治疗某些疾病中的使用,包括骨关节炎、类风湿性关节炎、糖尿病性神经病、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛,以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
  • [EN] PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILES COMME INHIBITEURS DE FAAH
    申请人:MERCK & CO INC
    公开号:WO2009151991A1
    公开(公告)日:2009-12-17
    The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease
    本发明涉及某些咪唑衍生物,其可用作脂肪酰胺水解酶(FAAH)的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方,以及这些化合物及其配方在治疗某些疾病中的使用,包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛,以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
  • [EN] OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS D'OXAZOLE UTILES COMME INHIBITEURS DE FAAH
    申请人:MERCK & CO INC
    公开号:WO2010017079A1
    公开(公告)日:2010-02-11
    The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.
    本发明涉及某些噁唑衍生物,其可用作脂肪酸酰胺水解酶(FAAH)的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方,以及这些化合物及其配方在治疗某些疾病中的使用,包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛,以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
  • Triazolopyrimidine cannabinoid receptor 1 antagonists
    申请人:Wu Gang
    公开号:US20060287341A1
    公开(公告)日:2006-12-21
    The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R 1 , R 2 , R 3 , R 4 and R 5 are described herein.
    本申请描述了根据公式I和II的化合物,包括至少一种符合公式I或II的化合物的药物组合物,以及可选地包括一种或多种额外治疗剂的药物组合物,并且使用根据公式I和II的化合物进行治疗的方法,无论是单独使用还是与一种或多种额外治疗剂结合使用。这些化合物具有以下一般公式:包括所有的前药、溶剂化合物、药用可接受盐和立体异构体,其中R1、R2、R3、R4和R5如本文所述。
  • OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH
    申请人:CHOBANIAN Harry
    公开号:US20110021531A1
    公开(公告)日:2011-01-27
    The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.
    本发明涉及某些噁唑衍生物,其可用作脂肪酸酰胺水解酶(FAAH)的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方,以及这些化合物及其配方在治疗某些疾病中的使用,包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛,以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
查看更多

同类化合物

2-花生酰基甘油 2-花生基甘油醚 2-花生基甘油-d5 2-eicosa-5,8,11,14,17-pentaenoyl glycerol (Z)-1,3-dihydroxypropan-2-yl icos-11-enoate 2-arachidonoyl glycerol-d8 1,3-dihydroxypropan-2-yl (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate 1,3-dihydroxypropan-2-yl (5Z,8Z,11Z,14E)-icosa-5,8,11,14-tetraenoate 1,3-dihydroxypropan-2-yl (5Z,8Z,11E,14E)-icosa-5,8,11,14-tetraenoate 19,21-Dihydroxy-20-icosa-5,8,11,14-tetraenoxyhenicosa-9,12-dienoic acid 1,1-Dideuterio-2-icosa-5,8,11,14-tetraenoxypropane-1,3-diol 3-Hydroxy-2-icosa-5,8,11,14-tetraenoyloxypropanoic acid 21,23-Dihydroxy-22-icosa-5,8,11,14-tetraenoxytricosa-5,8,11,14-tetraenoic acid 2-Icosa-5,8,11,14-tetraenoxy-4-(2-phenoxyethoxy)butane-1,3-diol [1,3-Dihydroxy-23-(2-hydroxyethylamino)-23-oxotricosa-9,12,15,18-tetraen-2-yl] icosa-5,8,11,14-tetraenoate 1,3-dihydroxypropan-2-yl (5Z,8E,11E,14Z)-icosa-5,8,11,14-tetraenoate 1,3,4,5,6-Pentahydroxyhexan-2-yl 5,9-dihydroxy-2,4,6,8,10,12,14,16,18-nonamethyl-13-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-2,6,10-trienoate 1,2,4,5,6-Pentahydroxyhexan-3-yl 5,9-dihydroxy-2,4,6,8,10,12,14,16,18-nonamethyl-13-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-2,6,10,14-tetraenoate 1,3-Dihydroxypropan-2-yl icos-11-enoate 1,3,4,5,6-Pentahydroxyhexan-2-yl 5,9-dihydroxy-2,4,6,8,10,12,14,16,18-nonamethyl-13-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-2,6,10,14-tetraenoate 1,3-Dihydroxypropan-2-yl 3,7-dihydroxyicosanoate 1,3-Dihydroxypropan-2-yl 3-acetyloxy-6-hydroxyicosanoate 1,3-Dihydroxypropan-2-yl 11-hydroxyicosa-5,8,12,14-tetraenoate 1,3-Dihydroxypropan-2-yl icosa-11,14,17-trienoate 2-arachidonoylglycerol 1,2,4,5,6-Pentahydroxyhexan-3-yl 13-[6-(acetyloxymethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-5,9-dihydroxy-2,4,6,8,10,12,14,16,18-nonamethylicosa-2,6,10-trienoate 1,3-Dihydroxypropan-2-yl 3,9-dihydroxyicosanoate 1,3-Dihydroxypropan-2-yl icosa-11,14-dienoate 1,2,4,5,6-Pentahydroxyhexan-3-yl 5,9-dihydroxy-2,4,6,8,10,12,14,16,18-nonamethyl-13-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-2,6,10-trienoate 1,3-Dihydroxypropan-2-yl 3,8-diacetyloxyicosanoate 1,3-Dihydroxypropan-2-yl 3-acetyloxy-8-hydroxyicosanoate 1,3-Dihydroxypropan-2-yl 3,8-dihydroxyicosanoate 1,3-Dihydroxypropan-2-yl 3,9-diacetyloxyicosanoate 1,3-Dihydroxypropan-2-yl icosa-5,11,14-trienoate 1,3-Dihydroxypropan-2-yl 3-acetyloxy-7-hydroxyicosanoate 2-Hydroxy-1-(hydroxymethyl)ethyl icosanoate 1,3,4,5-Tetrahydroxypentan-2-yl 5,9-dihydroxy-2,4,6,8,10,12,14,16,18-nonamethyl-13-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-2,6,10,14-tetraenoate 1,3-Dihydroxypropan-2-yl icosa-8,11,14,17-tetraenoate 1,3-Dihydroxypropan-2-yl icosa-5,8,11,14,17-pentaenoate 1,2,4,5-Tetrahydroxypentan-3-yl 5,9-dihydroxy-2,4,6,8,10,12,14,16,18-nonamethyl-13-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-2,6,10,14-tetraenoate 1,3-Dihydroxypropan-2-yl icosa-8,11,14-trienoate 2-AG ether;2-Arachidonylglyceryl ether;HU 310 1,3-Dihydroxypropan-2-yl icosa-5,8,11-trienoate 1,3-Dihydroxypropan-2-yl 3-acetyloxyicosanoate 1,3-Dihydroxypropan-2-yl 3-acetyloxy-9-hydroxyicosanoate 1,3-Dihydroxypropan-2-yl 3,6-dihydroxyicosanoate